|February 16, 2022
|Dissecting Intratumor Heterogeneity in Kidney Cancer Using Deep Learning
|Individual Investigator Research Awards for Computational Biology
|The University of Texas Southwestern Medical Center
|Principal Investigator/Program Director
|Kidney and Renal Pelvis
Metastatic clear cell renal cell carcinoma is treated with therapies that target the tumor blood vessels and/or with immune checkpoint inhibitors (ICIs) that use the body's immune system to fight the cancer. However, none of these treatments uniformly benefit all patients and many patients suffer from lot of side effects from these drugs. Different drugs target different molecular pathways and benefit different groups of patients. We therefore need markers that can be used in the clinic and tell us if the patient will respond to one group of drugs or not (ICI or those that target blood vessels).
Recently, data from a clinical trial showed that a set of gene expression signature could predic...